BR112014029834A2 - polipeptídeo ou um sal, formulação farmacêutica, polipeptídeo ou sal, métodos de determinação se as células t reconhecem um polipeptídeo ou sal, de tratamento de um indivíduo ou de prevenção de uma alergia em um indivíduo a cladosporium e/ou alternaria, e para preparar uma formulação farmacêutica, e, uso de um polipeptídeo ou sal - Google Patents
polipeptídeo ou um sal, formulação farmacêutica, polipeptídeo ou sal, métodos de determinação se as células t reconhecem um polipeptídeo ou sal, de tratamento de um indivíduo ou de prevenção de uma alergia em um indivíduo a cladosporium e/ou alternaria, e para preparar uma formulação farmacêutica, e, uso de um polipeptídeo ou salInfo
- Publication number
- BR112014029834A2 BR112014029834A2 BR112014029834A BR112014029834A BR112014029834A2 BR 112014029834 A2 BR112014029834 A2 BR 112014029834A2 BR 112014029834 A BR112014029834 A BR 112014029834A BR 112014029834 A BR112014029834 A BR 112014029834A BR 112014029834 A2 BR112014029834 A2 BR 112014029834A2
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptide
- salt
- individual
- pharmaceutical formulation
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01138—Mannitol 2-dehydrogenase (NADP+) (1.1.1.138)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
- C12Y102/01003—Aldehyde dehydrogenase (NAD+) (1.2.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
Abstract
1 / 1 resumo âpolipeptãdeo ou um sal, formulaãão farmacãutica, polipeptãdeo ou sal, mãtodos de determinaãão se as cãlulas t reconhecem um polipeptãdeo ou sal, de tratamento de um indivãduo ou de prevenãão de uma alergia em um indivãduo a cladosporium e/ou alternaria, e para preparar uma formulaãão farmacãutica, e, uso de um polipeptãdeo ou salâ polipeptãdeos que podem ser usados para a prevenã§ã£o ou tratamento de alergia aos mofos dos gãªneros cladosporium e/ou alternaria, tãªm atã© 30 aminoã¡cidos de comprimento e compreendem: (i) a sequãªncia de aminoã¡cidos: (a) ggykaavrptmle (seq id no: 35; cla35), (b) aevyqklksltkk (seq id no: 31; cla16), (c) vaityasraqgae (seq id no: 32; cla25), (d) ghhfkergtgslvit (seq id no: 33; cla26), ou (e) anytqtktvsirl (seq id no: 34; cla29); ou (ii) uma sequãªncia variante contendo epãtopo de cã©lulas t que ã© uma referida sequãªncia de aminoã¡cidos (i) tendo atã© seis modificaã§ãµes de aminoã¡cido, cada sendo independentemente uma deleã§ã£o, substituiã§ã£o ou inserã§ã£o.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1209862.0A GB201209862D0 (en) | 2012-06-01 | 2012-06-01 | Cladosporium peptides |
PCT/GB2013/051440 WO2013179044A2 (en) | 2012-06-01 | 2013-05-30 | Cladosporium peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014029834A2 true BR112014029834A2 (pt) | 2017-07-25 |
Family
ID=46582262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014029834A BR112014029834A2 (pt) | 2012-06-01 | 2013-05-30 | polipeptídeo ou um sal, formulação farmacêutica, polipeptídeo ou sal, métodos de determinação se as células t reconhecem um polipeptídeo ou sal, de tratamento de um indivíduo ou de prevenção de uma alergia em um indivíduo a cladosporium e/ou alternaria, e para preparar uma formulação farmacêutica, e, uso de um polipeptídeo ou sal |
Country Status (16)
Country | Link |
---|---|
US (1) | US9850281B2 (pt) |
EP (1) | EP2855514A2 (pt) |
JP (1) | JP2015520171A (pt) |
KR (1) | KR20150016622A (pt) |
CN (1) | CN104507960A (pt) |
AU (1) | AU2013269327A1 (pt) |
BR (1) | BR112014029834A2 (pt) |
CA (1) | CA2875131A1 (pt) |
CL (1) | CL2014003289A1 (pt) |
EA (1) | EA201492270A1 (pt) |
GB (2) | GB201209862D0 (pt) |
HK (1) | HK1202554A1 (pt) |
IL (1) | IL235842A0 (pt) |
MX (1) | MX2014014460A (pt) |
SG (1) | SG11201407945SA (pt) |
WO (1) | WO2013179044A2 (pt) |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT400722B (de) * | 1993-08-27 | 1996-03-25 | Biomay Prod & Handel | Rekombinante cladosporium herbarum allergene |
AT401181B (de) | 1994-11-02 | 1996-07-25 | Biomay Prod & Handel | Rekombinante dna moleküle |
AT403166B (de) * | 1995-03-02 | 1997-11-25 | Biomay Prod & Handel | Rekombinante dna moleküle, die für polypeptide kodieren, die die antigenität der allergene clah8 und clah12 besitzen |
CA2217173C (en) | 1997-11-25 | 2008-04-01 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health | Isolation of a cdna clone encoding a subunit of the alternaria alternata major allergen alt a 1, and production of recombinant protein thereof |
WO2003083098A2 (de) | 2002-03-28 | 2003-10-09 | Biomay Produktions- Und Handels-Aktiengesellschaft | Nucleinsäuresequenz und protein sowie polypeptide kodierend für mannit-dehydrogenasen oder deren teile sowie deren herstellung und verwendung in diagnostik und therapie |
WO2009022154A2 (en) | 2007-08-15 | 2009-02-19 | Circassia Limited | Peptide with multiple epitopes |
CN101178406A (zh) | 2007-12-05 | 2008-05-14 | 杭州浙大生物基因工程有限公司 | 过敏原特异性抗体IgE ELISA检测试剂盒及其制备方法 |
WO2010018384A1 (en) * | 2008-08-15 | 2010-02-18 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of il-10 production |
CN101387643A (zh) | 2008-10-20 | 2009-03-18 | 杭州浙大生物基因工程有限公司 | 多通道过敏原快速检测试剂盒及其制备方法 |
CN101393215A (zh) | 2008-11-17 | 2009-03-25 | 杭州浙大生物基因工程有限公司 | 多通道吸入型过敏原快速检测试剂盒及其制备方法 |
GB0821806D0 (en) | 2008-11-28 | 2009-01-07 | Circassia Ltd | Compositions with reduced dimer formation |
GB201002559D0 (en) | 2010-02-15 | 2010-03-31 | Circassia Ltd | Birch peptides for vaccine |
CN102212531A (zh) | 2010-04-02 | 2011-10-12 | 复旦大学 | 一种重组多主枝孢霉变应原Cla h8蛋白的制备方法及其用途 |
BR112013009068A2 (pt) | 2010-10-15 | 2016-07-19 | Alk Abelló As | supressão de uma resposta imune de hipersensibilidade com antígeno não relacionado derivado de material fonte de alérgeno |
US20150004189A1 (en) * | 2012-02-07 | 2015-01-01 | La Jolla Institute For Allergy And Immunology | Epitopes from allergen proteins and methods and uses for immune response modulation |
-
2012
- 2012-06-01 GB GBGB1209862.0A patent/GB201209862D0/en not_active Ceased
-
2013
- 2013-05-30 KR KR1020147037164A patent/KR20150016622A/ko not_active Application Discontinuation
- 2013-05-30 EP EP13726838.9A patent/EP2855514A2/en not_active Withdrawn
- 2013-05-30 JP JP2015514590A patent/JP2015520171A/ja active Pending
- 2013-05-30 MX MX2014014460A patent/MX2014014460A/es unknown
- 2013-05-30 CN CN201380040588.7A patent/CN104507960A/zh active Pending
- 2013-05-30 US US14/403,462 patent/US9850281B2/en not_active Expired - Fee Related
- 2013-05-30 BR BR112014029834A patent/BR112014029834A2/pt not_active IP Right Cessation
- 2013-05-30 AU AU2013269327A patent/AU2013269327A1/en not_active Abandoned
- 2013-05-30 SG SG11201407945SA patent/SG11201407945SA/en unknown
- 2013-05-30 CA CA2875131A patent/CA2875131A1/en not_active Abandoned
- 2013-05-30 WO PCT/GB2013/051440 patent/WO2013179044A2/en active Application Filing
- 2013-05-30 EA EA201492270A patent/EA201492270A1/ru unknown
- 2013-05-30 GB GB1422973.6A patent/GB2518092A/en not_active Withdrawn
-
2014
- 2014-11-23 IL IL235842A patent/IL235842A0/en unknown
- 2014-12-01 CL CL2014003289A patent/CL2014003289A1/es unknown
-
2015
- 2015-03-19 HK HK15102838.5A patent/HK1202554A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EA201492270A1 (ru) | 2015-09-30 |
GB2518092A (en) | 2015-03-11 |
JP2015520171A (ja) | 2015-07-16 |
US20150218215A1 (en) | 2015-08-06 |
WO2013179044A3 (en) | 2014-03-06 |
KR20150016622A (ko) | 2015-02-12 |
AU2013269327A1 (en) | 2014-12-18 |
SG11201407945SA (en) | 2014-12-30 |
US9850281B2 (en) | 2017-12-26 |
GB201209862D0 (en) | 2012-07-18 |
CN104507960A (zh) | 2015-04-08 |
CL2014003289A1 (es) | 2015-05-22 |
CA2875131A1 (en) | 2013-12-05 |
WO2013179044A2 (en) | 2013-12-05 |
IL235842A0 (en) | 2015-01-29 |
EP2855514A2 (en) | 2015-04-08 |
HK1202554A1 (en) | 2015-10-02 |
MX2014014460A (es) | 2015-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018000232A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
BR112017025108A2 (pt) | compostos seletivos de pyy e usos dos mesmos | |
MX2023003875A (es) | Formulacion de una vacuna peptidica. | |
BR112018071466A2 (pt) | novos peptídeos de ligação a cd1d imunogênicos | |
CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
BR112012020953A2 (pt) | produto, uso do mesmo, metodo para prevencao e/ou tratamento de fibrose corneana ou opacidade corneana e composicao farmaceutica oftalmica | |
BR112016019735A2 (pt) | fhbp, polipeptídeo, plasmídeo ou outro ácido nucleico, célula hospedeira, vesículas de membrana, e, composição imunogênica | |
BR112017019343A2 (pt) | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas | |
AR102445A1 (es) | COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA | |
BR112015009280A2 (pt) | preparações liofilizadas de melfalana flufenamida | |
BR112017013453A2 (pt) | novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório | |
ES2671434T3 (es) | Antagonistas de Kv1.3 y métodos de uso | |
BR112013013548B8 (pt) | Proteína de fusão anticancerígena | |
AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
BR112013019513A2 (pt) | métodos para o tratamento de úlceras diabéticas do pé | |
BR112014023572A2 (pt) | método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes | |
BR112015030355A8 (pt) | uso de uma proteína ou um polipeptídeo de adenilil ciclase tipo 6 (ac6) incompetente com a adenosina monofosfato cíclico (incompetente com camp) ou um gene ou ácido nucléico que codifica ac6mut, e, formulação | |
TR201910117T4 (tr) | OspA nın mutant fragmanları ve bunlara ilişkin yöntemler ve kullanımları. | |
EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
CL2021000129A1 (es) | Apirasas solubilizadas, métodos y usos | |
BR112015019568A2 (pt) | Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo | |
BR112014028130A2 (pt) | Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos | |
BR112017006969A2 (pt) | peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno | |
BR112016016917A2 (pt) | Sistema de administração de fármaco | |
BR112014022958A2 (pt) | peptídeo mimético de gp41, composição imunogênica, e, método para obter uma resposta imune em um hospedeiro mamífero |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |